Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 7/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323362 | 1.00 | SCN9A (0.55) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL20744476 | 0.93 | RBP4 (0.54) | SCN9AHTR6FEN1ALOX5APRBP4 | |
| SCHEMBL27157955 | 0.90 | SCN9A (0.55) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL27158910 | 0.89 | SCN9A (0.55) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL4509555 | 0.88 | SCN9A (0.54) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL3325111 | 0.87 | SCN9A (0.58) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL3325117 | 0.87 | SCN9A (0.58) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL25200987 | 0.86 | RBP4 (0.54) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL3323958 | 0.86 | HTR6 (0.54) | SCN9AHTR6BCHEACKR3FEN1 | |
| SCHEMBL3323952 | 0.86 | HTR6 (0.54) | SCN9AHTR6BCHEACKR3FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | SCN9A 818/4885HTR6 832/4885BCHE 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.